



01-23-02

PATENT  
674515-2003

1712

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Barry C. Holdstock et al.  
Filed : October 15, 2001  
Serial No. : 09/977,880  
For : PROCESS FOR THE PREPARATION OF A DIOL

745 Fifth Avenue  
New York, NY 10151

**EXPRESS MAIL**

Mailing Label Number: EV001418120US

Date of Deposit: January 17, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Honorable Commissioner of Patents and Trademarks, Washington, DC 20231.

Charles Jackson  
(Typed or printed name of person mailing paper or fee)

Charles Jackson  
(Signature of person mailing paper or fee)

RECEIVED  
JAN 28 2002  
TC 1700

**CLAIM OF PRIORITY**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants hereby claim of priority under 35 U.S.C. §119 and for 120, from  
U.K Application No. 9908808.0, a certified copy of which is enclosed.

Acknowledgment of the claim of priority and of the receipt of said certified copy  
are respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP

By: Thomas J. Kowalski  
THOMAS J. KOWALSKI, Reg. No. 32,147  
(212) 588-0800

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

RECEIVED  
JAN 28 2002  
TC 1700

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation and Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein together with the Statement of inventorship and of right to grant of a Patent (Form 7/77), which was subsequently filed.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.



In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 8 November 2001.

**THIS PAGE BLANK (USPTO)**



# Request for a grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference P005627GB DAA

2. Patent application number  
(The Patent Office will fill in this part)

9908808.0

3. Full name, address and postcode of the or of each applicant  
(underline all surnames)

Hydron Limited  
Hawley Lane  
Farnborough  
Hampshire  
GU14 8EQ

16 APR 1999

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

6512673001

4. Title of the invention Process

5. Name of your agent (if you have one)

D YOUNG & CO

"Address for service" in the United Kingdom to which all correspondence should be sent  
(including the postcode)

21 NEW FETTER LANE  
LONDON  
EC4A 1DA

Patents ADP number (if you have one)

59006

6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or each of these earlier applications and (if you know it) the or each application number.

Country

Priority application  
number  
(if you know it)

Date of filing  
(day/month/year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and filing date of the earlier application

Number of earlier  
application

Date of filing  
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:  
a) any applicant named in part 3 is not an inventor, or  
b) there is an inventor who is not named as an applicant, or  
c) any named applicant is a corporate body.  
See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0

Description 20

Claims(s) 3

Abstract 1

Drawing(s) 2

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0


Request for substantive examination (Patents Form 10/77) 0

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

  
D YOUNG & CO  
Agents for the Applicants

16/04/1999

12. Name and daytime telephone number of the person to contact in the United Kingdom D Alcock

01703 634816

### Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

### Notes


- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 01645 500505
- b) Write your answers in capital letters using black ink or you may type them
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.




Patents Form 7/77

Patents Act 1977  
(Rule 15)

The  
Patent  
Office



Statement of inventorship and  
of right to grant of a patent



The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference P005627GB DAA
2. Patent application number (if you know it) 9908808.0
3. Full name of the or of each applicant Hydron Limited
4. Title of the invention Process
5. State how the applicant(s) derived the right from the inventor(s) to be granted a patent By virtue of contract of employment
6. How many, if any, additional Patents Forms 7/77 are attached to this form? (see note (c)) 1

7. I/We believe that the person(s) named over the page (and on any extra copies of this forms) is/are the inventor(s) of the invention which the above patent relates to.

Signature

Date

*D Young & Co*

D YOUNG & CO

Agents for the Applicants

30 Mar 2000

8. Name and daytime telephone number of person to contact in the United Kingdom 023 80634816 David Alcock

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write answers in capital letters using black ink or you may type them.

c) If there are more than three inventor, please write the names and addresses of the other inventors on the back of another Patents Form 7/77 and attach it to this form.

d) When an application does not declare any priority, or declares priority from an earlier UK application, you must provide enough copies of this form so that the Patent Office can send one to each inventor who is not an applicant.

e) Once you have filled in the form you must remember to sign and date it.

Enter the full names, addresses and postcodes of the inventors in the boxes and underline the surnames

Surname	<u>HOLDSTOCK</u>
First Names	Barry Charles
Address	Flat 12 Kingston Court 82 Maple Road Surbiton Surrey KT6 4AL United Kingdom
Patents ADP number (if you know it): 3314390001	

Surname	<u>GLASBEY</u>
First Names	Trevor Owen
Address	27 Kingston Road Camberley Surrey GU15 4AG United Kingdom
Patents ADP number (if you know it): 7247554001	

Surname	_____
First Names	_____
Address	_____
Patents ADP number (if you know it): _____	

**Reminder:**  
**Have you signed the form?**



### Process

The present invention relates to a process for the preparation of a diol. The diol may be used subsequently used as a monomer for the preparation of a polymeric device or material such as a hemocompatible coating, medical device, water soluble polymer  
5 material, paint, water borne coating or an ocular device (such as a contact lens).

Polymers made from polymerisable monomers have wide spread applications. For example, polymers are used as additives for coating applications, such as paints and  
10 adhesives. Polymers are also used to prepare lenses, such as contact lenses.

Polymers are prepared by polymerising one or more types of polymerisable monomers, such as by emulsion polymerisation, solution polymerisation, suspension polymerisation or bulk polymerisation. The monomer(s) may be polymerised in the presence of optional  
15 ingredients such as any one of emulsifiers, stabilisers, surface active agents, initiators (such as photoinitiators), inhibitors, dispersants, oxidising agents, reducing agents, viscosity modifiers, catalysts, binders, activators, accelerators, tackifiers, plasticizers, saponification agents, chain transfer agents, surfactants, fillers, dyes, metal salts, and solvents.

20 There are numerous references on polymerisation of polymerisable monomers. For example, some teachings may be found in "Emulsion Polymerization: Theory and Practice" by D. C. Blackley (published by Wiley in 1975) and "Emulsion Polymerization" by F. A. Bovey *et al.* (published by Interscience Publishers in 1965). For example, a  
25 polymer can be prepared from monomers such as methyl acrylate, ethyl acrylate, butyl acrylate, 2-ethylhexyl acrylate, decyl acrylate, methyl methacrylate, ethyl methacrylate, butyl methacrylate, styrene, butadiene, ethylene, vinyl acetate, vinyl esters, C<sub>9</sub>, C<sub>10</sub> and C<sub>11</sub> tertiary monocarboxylic acids, vinyl chloride, vinyl pyridine, vinyl pyrrolidine, vinylidene chloride, acrylonitrile, chloroprene, acrylic acid, methacrylic acid, itaconic  
30 acid, maleic acid and fumaric acid.

Examples of further teachings on polymerisation of polymerisable monomers may be found in "Vinyl and Related Polymers" by C.E. Schildknecht (New York: John Wiley & Sons 1952) and "Monomeric Acrylic Esters" by E.H. Riddle (New York: Reinhold Publishing Corp. 1954), and by A.G. Alexander (J Oil Colour Chemists' Association  
5 [1962] 45 12) and G.G. Greth and J.E. Wilson (J Appl Polymer Sci [1961] 5 135).

More recent teachings regarding polymerisation methods may be found in EP-A-0622378, EP-A-0634428, EP-A-0623632, EP-A-0635522, EP-A-0633273, EP-A-0632157, EP-A-0630908, EP-A-0630641, EP-A-0628614, EP-A-0628610, EP-A-0622449, EP-A-  
10 0626430 and EP-A-0625529.

As mentioned above, one particular application of polymers is in the preparation of lenses, especially contact lenses or intraocular lenses. Examples of teachings for the preparation of contact lenses may be found in EP-A-0359539, which discloses a method of forming a  
15 soft contact lens. Other documents that describe the preparation of contact lenses include WO-A-9502617 which discloses a contact lens made from a vinyl polymer bearing phosphonium groups, JP-A-06313009 which discloses a contact lens made from a polymer having a terminal phosphoryl-choline group, WO-A-9429756 which discloses a gas permeable ocular lens made from a block copolymer and a second polymer  
20 component, WO-A-9409042 which discloses a contact lens comprising polymer and a UV absorbing constituent, and WO-A-9211407 which discloses a tinted contact lens comprising a polymer and a dye wherein the lens is prepared by incorporating a dye into a hydrophilic polymer while the polymer is being formed. Further documents describing preparing contact lenses and the like from polymerisable monomers include EP-A-  
25 0574352, EP-A-0439394, EP-A-0378511 and EP-A-0424520.

Whilst polymers can be fairly easily prepared from polymerisable monomers there can be a problem in reliably and cheaply obtaining suitable monomers in a satisfactory pure form. In this regard, many desired polymerisable monomers are supplied with impurities. These  
30 impurities can be detrimental to the final product.

Impurities which are particularly problematic are compounds which act as cross-linkers during the polymerisation of the monomer. Whilst the presence of cross-linkers is often required during the polymerisation of a monomer, the presence of impurities which act as cross-linkers may cause at least two problems. Firstly, to achieve a desired degree of cross-linking during polymerisation, the addition of further cross-linker is often required. However, if the amount of cross-linker impurity present in the monomer is not known, the required amount of additional cross-linker cannot be readily calculated. Thus, controlling the degree of cross-linking may be difficult. Moreover, if cross-linker is present in an amount greater than is necessary to provide the required degree of cross-linking, cross-linker must be removed prior to polymerisation.

An example of a monomer in which impurities, in particular cross-linkers, are a problem is glyceryl methacrylate (GMA) which is a preferred monomer for preparing contact lenses. Examples of documents mentioning the use of such a monomer include US-A-5236969, JP-A-04335007, GB-A-2180243 and EP-A-0100381. There are two major problems with GMA. First, the impurities often vary from batch to batch and so make it difficult to have a standard purification protocol. Second, GMA is a very expensive monomer.

There have been attempts to prepare GMA from other monomers, such as isopropylidene glyceryl methacrylate (IPGMA) [i.e. 2,2-dimethyl-1,3-dioxolan-4-yl methyl methacrylate (GMAK)]. One such process for preparing GMA is disclosed in US-A-4056496 wherein the process includes reacting IPGMA with sulphuric acid and hydroquinone for a period of 16 hours.

Another process for preparing GMA, also mentioned in US-A-4056496, includes the hydrolysis of glycidyl methacrylate (GYMA) by treating GYMA with concentrated sulphuric acid for 6 days (M.F. Refojo [1965] Journal of Polymer Science 9 pp 3161-3170). This process is particularly disadvantageous because glycidyl methacrylate is highly toxic and carcinogenic. Moreover, glycidyl methacrylate is a cross-linker and further cross-linkers are formed during the reaction (particularly by the reaction of glycidyl methacrylate with GMA in the presence of acid). The presence of these cross-

linkers may require further purification steps or may be detrimental to any polymer prepared by polymerisation of the obtained monomer. Yet further the process of Refojo requires neutralisation of  $\text{H}_2\text{SO}_4$  with  $\text{Ba}(\text{OH})_2$  and extraction with a toxic flammable solvent.

5

The distillation of GMA to prepare purified GMA followed by addition of cross-linker is also practised in the art. Distillation is however both difficult and costly. GMA is high boiling and therefore costs of distillation are high. Distillation typically gives losses of 15-20% of the product to be purified. Moreover, GMA may polymerise during distillation and valuable monomer lost. Yet further, the equipment which may be required to perform the distillation e.g. falling film evaporator, is expensive

Clearly these prior art methods do not provide suitable control of the amount of cross-linker present in the monomer and therefore do not allow for control of the degree of cross-linking during polymerisation. The monomers obtained by the prior art may contain too much cross-linker for some applications or require expensive and difficult purification. Moreover, the prior art methods which attempt to provide pure monomer or to provide monomer comprising cross-linker are very labour intensive and include the use of hazardous chemicals, including toxic chemicals and flammable solvents, and hazardous process steps.

Further prior art methods for preparing GMA polymers are disclosed in US 4338419, FR 8207595, WO 93/0841 and Ezrielev et al, Vysokomol. Soedin, Ser. B, 20(10), 777-9, Hild, Makromol. Chem, 177, 1947-1972 (1976) and Beinert et al, Die Makromolekulare Chemie, 175, 2069-2077 (1974)


US-A-5532289 discloses a process for forming a soft contact lens. According to the claims of this patent the lens is formed from a copolymer consisting essentially of 2,3-dihydroxypropyl methacrylate (GMA) and 2-hydroxyethyl methacrylate. Hydroxyethyl methacrylate is sometimes referred to as HEMA. The process of US-A-5532289 requires

a pre-distillation step wherein GMA is distilled. Hence, the process of US-A-5532289 is laborious and costly.

WO 98/07055 discloses a process of preparing an ocular device (such as a contact lens) consisting essentially of GMA and HEMA, the process comprising the following steps: a) copolymerising a second monomer and a first monomer having attached to it a modifier group, thereby to form a first polymer having associated with it the modifier group; and b) modifying all or some the modifier group associated with the first polymer to form a second polymer different from the first polymer thereby to form the ocular device consisting essentially of GMA and HEMA.


The present invention seeks to overcome the problems associated with the known processes for preparing polymers.

According to a first aspect of the present invention there is provided a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I



comprising the steps of :

(i) contacting a compound of formula II



with an immobilised acid,

wherein X, Y, Z, R<sup>1</sup>, P and Q are independently selected from a hydrocarbyl group or hydrogen and wherein A is (CH<sub>2</sub>)<sub>n</sub> wherein n is 0 or 1;

(ii) neutralising the product of step (i) such that the cross-linker is formed.

5

According to a second aspect of the present invention there is provided an ocular device (such as a contact lens) prepared by the process according to the present invention.

By the term "cross-linker" we mean a compound which increases the degree of cross-linking of a monomer during polymerisation when compared to the polymerisation of the monomer in the absence of the cross-linker.

The present invention may provide a number of advantages.

15 The present invention may allow for the amount of cross-linker present in the composition to be controlled. Thus, the present invention provides a composition comprising a polymerisable monomer wherein the degree and/or rate of cross-linking of the polymerisable monomer may be controlled. Moreover, the concentration of cross-linker may be controlled such that further additions of cross-linker are possible to achieve the  
20 desired/optimum degree and/or rate of cross-linking during polymerisation.

The present invention has the advantage that because of the low initial cross-linker concentration in the monomer, controlled additions of further cross-linker to achieve the desired/optimum level are possible. In contrast, if monomer e.g. GMA, in accordance  
25 with the prior art is used, the level of cross-linker is often already too high to allow further additions without detriment to the mechanical properties of the final polymer, such as a lens.

It will be appreciated by a person skilled in the art that at least one of X, Y, Z or R<sup>1</sup> is a  
30 polymerisable group such that the compound of formula I is a polymerisable monomer. In a preferred aspect, R<sup>1</sup> is a polymerisable group.

In a preferred aspect of the process of the present invention the acid is a strong acid. By the term "strong acid" it is meant an acid having a pKa of less than 3.

- 5 In a preferred aspect of the process of the present invention the acid is immobilised on an ion exchange resin. Preferably the ion exchange resin is Amberlyst 15, obtainable from Röhm and Haas.

- 10 In a preferred aspect of the process of the present invention, the product of step (i) is neutralised by contacting the product with an immobilised alkali. Preferably the immobilised alkali is an immobilised hydroxide. More preferably the immobilised hydroxide is Amberjet 4400 (OH) obtainable from Röhm and Haas.

- 15 As mentioned above, preferably  $R^1$  is a polymerisable group. Preferably,  $R^1$  is selected from hydrocarbyl group, and hydrocarbyl esters, preferably unsaturated hydrocarbyl esters.

- 20 The term "hydrocarbyl group" as used herein means a group comprising at least C and H and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo-, alkoxy-, nitro-, hydroxy, carboxyl, epoxy, acrylic, hydrocarbon, N-acyl, or cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the hydrocarbyl group comprises more than one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may  
25 be linked *via* a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen and oxygen.

- 30 The term "hydrocarbyl ester" as used herein means a hydrocarbyl group comprising a -C(O)-O- group.

The term "unsaturated hydrocarbyl ester" as used herein means a hydrocarbyl ester comprising at least one carbon-carbon double bond or at least one carbon-carbon triple bond.

- 5 Preferably, the hydrocarbyl group is a linear or a branched group. The branched group may contain one or more branches.

In one aspect, the linear or a branched hydrocarbyl group may contain from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5  
10 carbon atoms, or from 1 to 3 carbon atoms.

The linear or a branched hydrocarbyl group may be saturated or unsaturated. In one aspect, the linear or a branched hydrocarbyl group may be saturated.

- 15 Preferably, the hydrocarbyl group comprises an alkyl backbone. The backbone may be interrupted by one or more non-alkyl groups. The non-alkyl groups may be selected from ester, ether and combinations thereof.

In one aspect, the alkyl backbone may contain from 1 to 20 carbon atoms, from 1 to  
20 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

The alkyl backbone may contain one or more alkyl groups branched from the alkyl backbone. In one aspect, each alkyl branch may contain from 1 to 20 carbon atoms,  
25 from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

The hydrocarbyl group may be a cyclic group. In this regard, the hydrocarbyl group can be a single ring group or a polycyclic group. Here, the term "polycyclic"  
30 includes fused and non-fused ring structures including combinations thereof.



At least one of the cyclic groups of the polycyclic group may be a heterocyclic group (a heterocycle) or a non-heterocyclic group.

The cyclic group or at least one of the cyclic groups of the polycyclic group may be a saturated ring structure or an unsaturated ring structure (such as an aryl group).


The hydrocarbyl group may contain any one or more of C, H, O, Si, N, P, halogen (including Cl, Br and I), S and P. In the preferred aspect wherein the hydrocarbyl group comprises an alkyl backbone, the alkyl backbone may be interrupted by one or more of any one or more of C, H, O, Si, N, P, halogen (including Cl, Br and I), S and P.

Preferably, the hydrocarbyl group is a hydrocarbon group.

Here the term "hydrocarbon group" means any one of an alkyl group, an alkenyl group, an alkynyl group, an acyl group, which groups may be linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

The hydrocarbon group may have from 1 to 20 carbon atoms, from 1 to 15 carbon atoms, from 1 to 10 carbon atoms, from 1 to 5 carbon atoms, or from 1 to 3 carbon atoms.

In a preferred embodiment  $R^1$  is a group of formula III



wherein  $R^2$  is selected from methyl, ethyl, propyl and butyl and  $R^3$  is selected from an unsaturated  $C_{1-5}$  alkyl. In a highly preferred embodiment  $R^2$  is  $CH_3$  and  $R^3$  is  $=CH_2$ .


Preferably, X, Y, P and Q of formulae given in the present specification are independently selected from a hydrocarbyl group and hydrogen. Preferably, the hydrocarbyl group is a hydrocarbon group. More preferably the hydrocarbyl group is a hydrocarbon group having from 1 to 20 carbons. Yet more preferably, the hydrocarbyl group is selected from methyl, ethyl, propyl and butyl

In a highly preferred embodiment X is H, Y is H, Z is H,  $n=0$ , P is  $CH_3$ , Q is  $CH_3$  and  $R^1$  is a group of formula III, in which  $R^2$  is  $CH_3$  and  $R^3$  is  $=CH_2$ .

When a compound of formula II is contacted with an immobilised acid to provide a polymerisable monomer of formula I, an acid is formed as a by-product during the reaction. For example, when 2,2-dimethyl-1,3-dioxolan-4-yl methyl methacrylate (GMAK) is contacted with an immobilised acid to provide GMA, methacrylic acid is formed albeit in a low concentration. In a preferred aspect of the present invention, the acid is neutralised in step (ii) such that a cross-linker is formed, wherein the cross-linker is glycerol dimethacrylate (DGMA).

20

Thus in a highly preferred aspect the present invention provides a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I




(I)

25

comprising the steps of

(i) contacting a compound of formula II



(II)

with an immobilised acid,

wherein X is H

5 Y is H


Z is H

A is  $(\text{CH}_2)_0$

P is  $\text{CH}_3$

Q is  $\text{CH}_3$

10 and wherein  $\text{R}^1$  is a group of formula III



(III)

in which  $\text{R}^2$  is  $\text{CH}_3$  and  $\text{R}^3$  is  $=\text{CH}_2$ ;

- 15 (ii) neutralising the product of step (i) by contacting the product with an immobilised hydroxide such that the cross-linker is formed, wherein the cross-linker is glycerol dimethacrylate.

In other words, in a highly preferred aspect, the present invention provides a process for  
 20 the preparation of a composition comprising glyceryl methacrylate (GMA), and glycerol dimethacrylate comprising the steps of (i) contacting (2,2-dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK) with an immobilised acid; (ii) neutralising the product of step (i) by contacting the product with an immobilised hydroxide such that the glycerol dimethacrylate is formed,

In a preferred embodiment of the present invention the immobilised acid is contacted with the compound of formula II in the presence of water.

5 In a preferred embodiment of the present invention the process further comprises providing means for containing the immobilised acid, contacting the immobilised acid with the compound of formula II and passing a gas through the immobilised acid. In this preferred aspect of the present invention extremely high conversions have been achieved. When GMAK was contacted with immobilised acid a conversion of >99.9% was achieved.

10

Preferably the gas contains oxygen. More preferably, the gas is air.

Preferably the means for containing the immobilised acid comprises a fluidised bed reactor.

15

In a further preferred aspect of the present invention the process comprises extracting the gas from the means for containing the immobilised acid after the gas has passed through the immobilised acid. The extracted gas may contain a reaction product of the contact of the compound of formula II with the immobilised acid. The reaction product  
20 may be of the formula  $P-C(O)-Q$ . By removing the reaction product, the equilibrium  $II \rightleftharpoons I + P-C(O)-Q$  will be driven towards I. Thus the rate of conversion and/or ultimate conversion of I will be increased and, in a preferred aspect, essentially quantitative conversion may be achieved.

25 It will be appreciated that reaction product  $P-C(O)-Q$  is a volatile compound. By the term "volatile compound" we mean that the compound has a boiling point of less than 150°C and/or is capable of forming an azeotrope with water.

Thus, in one preferred aspect of the present invention the compound of formula II is or is  
30 part of a polymer. However, as explained above, the compound of formula II is preferably a monomer.

In a preferred aspect the process of the present invention further comprises the step of polymerising the polymerisable composition to provide a medical device, in particular an ocular device such as a contact lens.

5

The present invention is very advantageous for preparing ocular devices, such as contact lenses (both hard and soft contact lenses), intraocular lenses, interocular lenses and intercorneal implants, as well as prostheses and hydrogel articles. In this regard, the present invention not only enables the ocular devices to be made more easily but also it  
10 allows, by providing a greater choice of possible degrees and/or rates of cross-linking, greater control over any one of the shrinkage, the dimensional consistency, the swell, the water sensitivity, the hydrophobicity or the hydrophilicity, or combinations thereof, of the resultant polymer.

15 The medical device and/or polymerisable composition may also comprise conventional additional components such as any one or more of emulsifiers, stabilisers, surface active agents, initiators (such as photoinitiators), inhibitors, dispersants, oxidising agents, reducing agents, viscosity modifiers, catalysts, binders, activators, accelerators, tackifiers, plasticizers, saponification agents, chain transfer  
20 agents, cross-linking agents, surfactants, fillers, dyes, metal salts, and solvents.

By way of example, the surfactants and dispersants can be salts of fatty rosin and naphthenic acids, condensation products of naphthalene sulphonic acid and formaldehyde of low molecular weight, carboxylic polymers and copolymers of the  
25 appropriate hydrophile-lipophile balance, higher alkyl sulfates, such as sodium lauryl sulfate, alkyl aryl sulfonates, such as dodecylbenzene sulfonate, sodium or potassium isopropylbenzene sulfonates or isopropyl-naphthalene sulfonates; sulfosuccinates, such as sodium dioctylsulfosuccinate alkali metal higher alkyl sulfosuccinates, *e.g.* sodium octyl sulfosuccinate, sodium N-methyl-N-palmitoyl-taurate, sodium oleyl isethionate,  
30 alkali metal salts of alkylaryl-polyethoxyethanol sulfates or sulfonates, *e.g.* sodium t-octylphenoxy-polyethoxyethyl sulfate having 1 to 5 oxyethylene units. Typical

polymerisation inhibitors that can be used include hydroquinone, monomethyl ether, benzoquinone, phenothiazine and methylene blue.

In a preferred embodiment the dye is selected from the group consisting of 2-hydroxybenzophenone, oxidiazoles, salicylic acid, resorcinol monobenzoate, benzotriazole, preferably 2H-benzotriazole, benzothiazoloazine, preferably 2N-benzothi-azoloazine,  $\alpha$ -cyano- $\beta$ -phenylcinnamic acid, polyalkypiperidine and derivatives thereof.

10 Preferably, the dye is selected from benzotriazole, in particular 2H-benzotriazole and derivatives thereof.

The composition and/or medical device of the present invention may comprise one or more additional comonomers. Examples of the one or more additional comonomers that can be used in the present invention include one of: (alkyl and cycloalkyl) acrylates; (alkyl and cycloalkyl) methacrylates; free-radical polymerisable olefinic acids, including alkoxy-, alkylphenoxy-, alkylphenoxy-(polyethyleneoxide)-, vinyl ester-, amine substituted (including quaternary ammonium salts thereof), nitrile-, halo-, hydroxy-, and acid substituted (for example phospho- or sulpho-) derivatives thereof; and other suitable ethylenically unsaturated polymerisable moieties; including combinations thereof. Preferably the alkyl and cycloalkyl groups contain up to 20 carbon atoms, e.g. ( $C_1$ - $C_{20}$  alkyl and  $C_1$ - $C_{20}$  cycloalkyl) acrylates, and ( $C_1$ - $C_{20}$  alkyl and  $C_1$ - $C_{20}$  cycloalkyl) methacrylates. In more detail, typical comonomers include any one of methyl acrylate, ethyl acrylate, n-propyl acrylate, isopropyl acrylate, n-butyl acrylate, isobutyl acrylate, t-butyl acrylate, isobornyl acrylate, pentyl acrylate, hexyl acrylate, octyl acrylate, iso-octyl acrylate, nonyl acrylate, lauryl acrylate, stearyl acrylate, eicosyl acrylate, 2-ethylhexyl acrylate, cyclohexyl acrylate, cycloheptyl acrylate, methyl methacrylate, ethyl methacrylate, hydroxymethylacrylate, hydroxymethylmethacrylate, propyl methacrylate, n-butyl methacrylate, t-butyl methacrylate, isobutyl methacrylate, pentyl methacrylate, hexyl methacrylate, cyclohexyl methacrylate, 2-ethylhexyl methacrylate, isobornyl methacrylate, heptyl methacrylate, cycloheptyl methacrylate, octyl

methacrylate, iso-octyl methacrylate, nonyl methacrylate, decyl methacrylate, lauryl methacrylate, eicosyl methacrylate, dodecyl acrylate, pentadecyl acrylate, cetyl acrylate, stearyl acrylate, eicosyl acrylate, isodecyl acrylate, vinyl stearate, nonylphenoxy-(ethyleneoxide)<sub>1-20</sub> acrylate, octadecene, hexadecene, tetradecene, dodecene, dodecyl methacrylate, pentadecyl methacrylate, cetyl methacrylate, stearyl methacrylate, eicosyl methacrylate, isodecyl methacrylate, nonylphenoxy-(ethyleneoxide)<sub>1-20</sub> methacrylate, acrylic acid, methacrylic acid, fumaric acid, crotonic acid, itaconic acid, fumaric anhydride, crotonic anhydride, itaconic anhydride, maleic acid, maleic anhydride, styrene, alpha-methyl styrene, vinyl toluene, acrylonitrile, methacrylonitrile, ethylene, vinyl acetate, vinyl chloride, vinylidene chloride, acrylamide, methacrylamide, methacrylamide 2-cyanoethyl acrylate, 2-cyanoethyl methacrylate, dimethylaminoethyl methacrylate, dimethylaminopropyl methacrylate t-butylaminoethyl methacrylate, glycidyl acrylate, glycidyl methacrylate, glyceryl acrylate, glyceryl methacrylate, benzyl acrylate, benzyl methacrylate, phenyl acrylate, phenyl methacrylate, vinyl pyridine, vinyl pyrrolidine, siloxanes, silanes and mixtures thereof. Other polymerisable monomers are disclosed in US-A-2879178, US-A-3037006, US-A-3502627, US-A-3037969 and US-A-3497485.

Preferred comonomers include any one of glyceryl methacrylate (GMA), (2,2 dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK), hydroxy ethyl methacrylate (HEMA), methacrylic acid, acrylic acid, GYMA, N-vinyl pyrrolidone, alkyl methacrylates (such as C<sub>1-20</sub> alkyl methacrylates, more preferably C<sub>1-15</sub> alkyl methacrylates, more preferably C<sub>1-10</sub> alkyl methacrylates, more preferably C<sub>1-5</sub> alkyl methacrylates, such as methyl methacrylate), alkyl acrylates (such as C<sub>1-20</sub> alkyl acrylates, more preferably C<sub>1-15</sub> alkyl acrylates, more preferably C<sub>1-10</sub> alkyl acrylates, more preferably C<sub>1-5</sub> alkyl acrylates, such as methyl acrylate), aryl methacrylates, aryl acrylates, diacetone acrylamide, acrylamide, methacrylamide, N-alkyl acrylamides (such as C<sub>1-20</sub> N-alkyl acrylamides, more preferably C<sub>1-15</sub> N-alkyl acrylamides, more preferably C<sub>1-10</sub> N-alkyl acrylamides, more preferably C<sub>1-5</sub> N-alkyl acrylamides, such as methyl acrylamide), N-alkyl methacrylamides (such as C<sub>1-20</sub> N-alkyl methacrylamides, more preferably C<sub>1-15</sub> N-alkyl methacrylamides, more preferably C<sub>1-10</sub> N-alkyl methacrylamides, more preferably C<sub>1-5</sub>

N-alkyl methacrylamides, such as methyl methacrylamide), vinyl acetate, vinyl esters, styrene, other substituted olefins, N-dialkyl acrylamides (such as C<sub>1-20</sub> N-dialkyl acrylamides, more preferably C<sub>1-15</sub> N-dialkyl acrylamides, more preferably C<sub>1-10</sub> N-dialkyl acrylamides, more preferably C<sub>1-5</sub> N-dialkyl acrylamides, such as N N dimethyl acrylamide), N-dialkyl methacrylamides (such as C<sub>1-20</sub> N-dialkyl methacrylamides, more preferably C<sub>1-15</sub> N-dialkyl methacrylamides, more preferably C<sub>1-10</sub> N-dialkyl methacrylamides, more preferably C<sub>1-5</sub> N-dialkyl methacrylamides, such as N N dimethyl methacrylamide), 3-methacryloxypropyl tris (trimethylsilyl siloxy) silane (TRIS monomer), fluoro substituted alkyl and aryl acrylates and methacrylates (preferably  
5 wherein the alkyl is C<sub>1-20</sub> alkyl, more preferably C<sub>1-15</sub> alkyl, more preferably C<sub>1-10</sub> alkyl, more preferably C<sub>1-5</sub> alkyl), and combinations thereof.  
10

More preferred comonomers include any one of glyceryl methacrylate (GMA), (2,2 dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK), 2-hydroxy ethyl  
15 methacrylate (2-HEMA), methacrylic acid, acrylic acid and glycidyl methacrylate, or combinations thereof.

The lists of comonomers also include substituted derivatives of those monomers, such as halogenated monomers, especially fluorinated monomer derivatives, and acetal and ketal  
20 derivatives.

The polymerisable monomer of the composition of the present invention and the one or more additional comonomers may be selected so that the composition and/or ocular device of the present invention consists essentially of GMA and HEMA.  
25

In a preferred aspect the present invention also provides an ocular device (such as a contact lens) obtained by the process of the present invention wherein the ocular device comprises HEMA in amounts of from 80-20%; GMA in amounts of from 20-80% by weight; and optionally a cross-linking polymerised monomer in an amount of 5% or less;  
30 and wherein the ocular device contains less than 0.01% methacrylic acid.



In a preferred aspect of the present invention the compound of formula II is a derivative of GMA such as (2,2-dimethyl-1,3-dioxolan-4-yl) methyl methacrylate (GMAK). GMAK can be prepared following the teachings of Mori *et al* ([1994] *Macromolecules* 27 pp 35-39) and Oguchi *et al* *Polym Eng. Sci.* ([1990] 30 449). This preferred process of the present invention is also of particular interest as GMAK can be readily synthesised from cheap, commercially available materials and it can be prepared in a pure state, i.e. free from the substances normally present in commercial GMA, especially cross-linking substances.

10 In a preferred aspect the process of the present invention comprises the step of polymerising the polymerisable monomer of formula I. Any typical, suitable polymerisation method may be used. The preferred method is free radical polymerisation, thermal or UV initiated.

15 A polymer prepared in accordance with the present invention may be fabricated as buttons or cast moulded or spun cast lenses.

The invention will now be described, by way of example only, with reference to the accompanying drawings in which:-

20

Figure 1 shows a reaction scheme of a preferred process in accordance with the present invention.

Figure 2 shows a graph.

25 EXAMPLES

1. Conversion of GMAK To Glycerine Methacrylate (GMA)

The method involves the acid catalysed hydrolysis of the ketal (GMAK) with a strong acid cation exchange resin.

30

Reagents Employed

	GMAK (washed)	2880 ml
	Deionised water	921 ml
5	Amberlyst 15 (wet) cation exchange resin	288 g

GMAK was obtained was prepared by transesterification of methyl methacrylate and Solketal (2,2-dimethyl-4-hydroxymethyl-1,3-dioxolane).

- 10 Before use the Amberlyst 15 (wet) was repeatably washed with deionised water to remove acidic impurities.

3000 ml of GMAK is washed with its own volume of deionised water to remove any Solketal. If the GMAK contains a high concentration of Solketal separation will be  
15 difficult.

The reagents are placed in a 5 litre bottle and a stream (11 litre/min) of filtered air of ambient temperature (15 to 18°C) passed through the mixture for 48 hours.

- 20 The cation exchange resin is then filtered off using a Buchner funnel and flask.

288 g of well washed Amberjet 4400 (OH) anion exchange resin is added to the filtrate and stirred for one hour to neutralise the methacrylic acid. The resin is then filtered off using a Buchner funnel and flask.

25

The filtrate is transferred to a 2 litre amber glass bottle and a rapid stream of dry filtered air passed through to reduce the water content to < 3%. 50ppm of methyl ether of hydroquinone is added as an inhibitor.

A yield of 1860 g of GMA was obtained. The cross-linker content was 0.8% glyceryl methacrylate. Details of samples analysed by UV and RI detection are given below. The data are also illustrated in Figure 2.

Composition by UV Detector (%)					Composition by RI Detector (%)			
Sample	GMA	MEHQ	GDMA	GMAK	Glycerol	GMA	GDMA	GMAK
1	99.37	0.04	0.84	0.11	3.02	99.11	0.67	0.00
2	95.12	0.04	2.25	0.05	3.03	95.30	2.01	0.00
3	98.00	0.04	1.59	0.01	2.59	97.95	1.41	0.00
4	97.41	0.04	1.41	0.05	3.40	97.23	1.29	0.00
5	94.13	0.03	1.41	2.26	3.02	94.15	1.24	2.18
6	94.08	0.05	1.35	2.02	3.00	93.84	1.14	1.81
7	100.11	0.05	1.38	0.01	2.60	100.80	1.16	0.00
8	92.98	0.04	1.44	0.01	2.69	93.53	1.34	0.00
9	99.39	0.04	1.57	0.38	1.63	99.39	1.42	0.00
10	91.89	0.03	1.40	0.06	3.14	91.94	1.06	0.00
11	95.11	0.04	1.41	0.39	3.09	94.30	1.23	0.00
12	97.58	0.04	1.29	0.04	3.64	98.04	1.06	0.00
13	97.77	0.04	1.45	0.04	3.23	96.96	1.24	0.00
14	97.73	0.05	1.58	0.59	2.80	98.04	1.40	0.47
Mean	96.48	0.04	1.46	0.43	2.92	96.47	1.26	0.32
St. Dev	2.57	0.00	0.29	0.75	0.47	2.63	0.29	0.72

## 2. Cast Moulding

10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Azo-isobutyronitrile (AIBN) (0.2%) was dissolved in the mixture which was then filtered. The mixture was charged into polypropylene moulds which were assembled and heated to 120°C for 30 minutes. The cured lenses were ejected and equilibrated in saline solution. The resulting hydrogel lenses had a water content of 60%.

## 3. Spin Casting

10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Benzoin methyl ether (0.2%) was dissolved in the mixture which was then filtered. The mixture was charged into PVC moulds designed for spin casting. After passage through a bank of UV lamps the cured lenses were removed from the moulds by exposure to warm water and then equilibrated in saline.

## 4. Buttons

10g of GMA (prepared in Example 1) was blended with 10g of HEMA. Isopropyl perdicarbonate (0.1%) was dissolved in the mixture which was then filtered. The mixture

was charged into polypropylene button moulds which were sealed and immersed in a water bath. After 16 hours at 32° C the clear colourless buttons were ejected and heated to 120°C for 1 hour and allowed to cool to 50°C at a rate of 17°C/hr. Lenses were cut from the buttons and equilibrated in saline.


5

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry or related fields are intended to be within the scope of the following claims.

10  
15

CLAIMS


1. A process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I



(I)

comprising the steps of :

(i) contacting a compound of formula II



(II)

with an immobilised acid,

wherein X, Y, Z, R<sup>1</sup>, P and Q are independently selected from a hydrocarbyl group or hydrogen and wherein A is (CH<sub>2</sub>)<sub>n</sub> wherein n is 0 or 1;

(ii) neutralising the product of step (i) such that the cross-linker is formed.

2. A process according to claim 1 wherein the acid is a strong acid.


3. A process according to claim 1 or 2 wherein the acid is immobilised on an ion exchange resin.

4. A process according to any one of the preceding claims wherein X and Y are independently selected from hydrocarbon groups having from 1 to 20 carbon atoms and hydrogen.

5. A process according to any one of the preceding claims wherein R<sup>1</sup> is selected from hydrocarbon groups having from 1 to 20 carbon atoms, and hydrocarbyl esters, preferably unsaturated hydrocarbyl esters.

5

6. A process according any one the preceding claims wherein R<sup>1</sup> is a group of formula III



10 wherein R<sup>2</sup> is selected from methyl, ethyl, propyl and butyl and R<sup>3</sup> is selected from an unsaturated C<sub>1-5</sub> alkyl.

7. A process according to claim 6 wherein R<sup>2</sup> is CH<sub>3</sub> and R<sup>3</sup> is =CH<sub>2</sub>.

15 8. A process according to any one of the preceding claims wherein X is H, Y is H, Z is H, n=0, R<sup>1</sup> is a group of formula III, in which R<sup>2</sup> is CH<sub>3</sub> and R<sup>3</sup> is =CH<sub>2</sub>.

9. A process according to any one of the preceding claims comprising providing means for containing the immobilised acid, contacting the immobilised acid with the  
20 compound of formula II and passing a gas through the immobilised acid.

10. A process according to claim 9 wherein the gas is air.


11. A process according to claim 9 or 10 wherein the immobilised acid is contacted with  
25 the compound of formula II in the absence of an organic solvent.

12. A process according to any one of the preceding claims step (i) is performed in the presence of water.

13. A process according to any one of claims 9 to 12 wherein the means for containing the immobilised acid comprises a fluidised bed reactor.
14. A process according to any one of claims 9 to 13 wherein the process comprises  
5 extracting the gas from the means for containing the immobilised acid after the gas has passed through the immobilised acid.
15. A process according to any one of the preceding claims wherein the process further comprises the step of polymerising the polymerisable monomer of formula I.
- 10 16. A process according to claim 15 wherein acid formed during the process is not neutralised prior to polymerisation.
17. A process according to claim 16 wherein the acid is selected from methacrylic acid  
15 and acrylic acid.
18. A process according to claim 15, 16 or 17 further comprising forming an ocular device from the polymer.
- 20 19. A polymerisable monomer, polymer or composition obtainable in accordance with process as defined in any one of claims 1 to 18.
20. A polymerisable monomer, polymer or composition obtained in accordance with a process as defined in any one of claims 1 to 18.
- 25 21. An ocular device prepared in accordance with a process as defined in any one of claims 1 to 18.

## ABSTRACT


There is provided a process for the preparation of a polymerisable composition comprising a cross-linker and a polymerisable monomer of formula I



(I)

comprising the steps of :

(i) contacting a compound of formula II



(II)

with an immobilised acid,

wherein X, Y, Z, R<sup>1</sup>, P and Q are independently selected from a hydrocarbyl group or hydrogen and wherein A is (CH<sub>2</sub>)<sub>n</sub> wherein n is 0 or 1;

(ii) neutralising the product of step (i) such that the cross-linker is formed.

Figure 1



1/2




Figure 1

**THIS PAGE BLANK (USPTO)**

## Variation in composition during stage 2




Figure 2

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)